AstraZeneca to acquire radioconjugate biotech Fusion in $2.4bn deal
As AstraZeneca looks to move past chemotherapy and radiotherapy, it will enter a market firmly controlled by Novartis.
As AstraZeneca looks to move past chemotherapy and radiotherapy, it will enter a market firmly controlled by Novartis.
What's Your Reaction?
